SCHEMBL29629233

SCHEMBL29629233

CCNc1nccc(-c2sc(NC(=O)Nc3ccc(CN4CCN(C(C)C)CC4)c(C(F)(F)F)c3)nc2C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 8/20 0.47
NTRK1 P04629 2/20 0.47
NTRK2 Q16620 2/20 0.47
TEK Q02763 1/20 0.47
RET P07949 3/20 0.47
EGFR P00533 1/20 0.45
BRAF P15056 1/20 0.45
CDK8 P49336 7/20 0.45
CCNC P24863 4/20 0.45
CDK1 P06493 1/20 0.45
CDK2 P24941 1/20 0.45
SRC P12931 5/20 0.44
KDR P35968 2/20 0.44
MAP4K2 Q12851 2/20 0.43
MAPK14 Q16539 2/20 0.43
CHEK1 O14757 1/20 0.43
AURKA O14965 1/20 0.43
DAPK3 O43293 1/20 0.43
JAK2 O60674 1/20 0.43
PRKD3 O94806 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22684882 1.00 ABL1 (0.47) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068640 0.93 CDK8 (0.51) ABL1NTRK1NTRK2TEKRET
SCHEMBL29629257 0.93 CDK8 (0.51) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068654 0.93 RET (0.55) ABL1NTRK1NTRK2TEKRET
SCHEMBL29629256 0.93 RET (0.55) ABL1NTRK1NTRK2TEKRET
SCHEMBL29629211 0.92 EGFR (0.54) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068639 0.92 EGFR (0.54) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068622 0.91 CDK8 (0.54) ABL1NTRK1NTRK2TEKRET
SCHEMBL29629236 0.91 CDK8 (0.54) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068679 0.90 CDK8 (0.52) ABL1NTRK1NTRK2TEKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740484-B1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-09-11 EP disclosed
CN-111757881-B 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents 澳升医药公司 2024-05-07 CN disclosed
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-03-23 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 ABL1 268/4885NTRK1 2045/4885NTRK2 3568/4885
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents CDK8, CDK18, CDK9 ABL1 268/4885NTRK1 2045/4885NTRK2 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.